Mirova US’s Novo Nordisk NVO Stock Holding History

Mirova US’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,932	Closed	-$55K	–	28
2019 Q4	$55K	Buy	+1,932	New	+$53.5K	0.01%	27

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

EHC

Everett Harris & Co Los Angeles, California $7.77B AUM 9.43% 1-Year Est. Return

Mirova US's NVO Position: Q1 2020 in Review

Mirova US sold out of Novo Nordisk (NVO) in Q1 2020, closing a stake of 1,932 shares — an estimated $55K sold.

Mirova US first reported a position in NVO in Q4 2019 and held it in 1 quarter. The position peaked at $55K in Q4 2019. 644 funds tracked by Wall St. Rank hold NVO as of Q1 2020.

Mirova US reported no remaining Novo Nordisk position as of Q1 2020 after selling out during the quarter.
Mirova US sold 1,932 Novo Nordisk shares in Q1 2020, an estimated $55K.
Mirova US first reported a position in Novo Nordisk in Q4 2019 and held it in 1 quarter.
Mirova US's Novo Nordisk position peaked at $55K in Q4 2019.
644 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2020.

Based on Mirova US's 13F filing for Q1 2020, filed 13 May 2020.